These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

770 related items for PubMed ID: 30118353

  • 21. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
    Mamolo C, Harness J, Tan H, Menter A.
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):192-203. PubMed ID: 23294276
    [Abstract] [Full Text] [Related]

  • 22. Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review.
    Gratacós Masmitjà J, González Fernández CM, Gómez Castro S, Rebollo Laserna FJ.
    Adv Ther; 2021 Feb; 38(2):868-884. PubMed ID: 33331985
    [Abstract] [Full Text] [Related]

  • 23. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].
    Sonomoto K, Tanaka Y.
    Nihon Rinsho Meneki Gakkai Kaishi; 2015 Feb; 38(6):443-7. PubMed ID: 27118331
    [Abstract] [Full Text] [Related]

  • 24. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
    Menter A, Papp KA, Tan H, Tyring S, Wolk R, Buonanno M.
    J Drugs Dermatol; 2014 Mar; 13(3):252-6. PubMed ID: 24595567
    [Abstract] [Full Text] [Related]

  • 25. Small molecule therapy for managing moderate to severe psoriatic arthritis.
    Costa L, Del Puente A, Peluso R, Tasso M, Caso P, Chimenti MS, Sabbatino V, Girolimetto N, Benigno C, Bertolini N, Del Puente A, Perricone R, Scarpa R, Caso F.
    Expert Opin Pharmacother; 2017 Oct; 18(15):1557-1567. PubMed ID: 28891341
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
    Cohen SB, Koenig A, Wang L, Kwok K, Mebus CA, Riese R, Fleischmann R.
    Clin Exp Rheumatol; 2016 Oct; 34(1):32-6. PubMed ID: 26575982
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
    Mease P, Charles-Schoeman C, Cohen S, Fallon L, Woolcott J, Yun H, Kremer J, Greenberg J, Malley W, Onofrei A, Kanik KS, Graham D, Wang C, Connell C, Valdez H, Hauben M, Hung E, Madsen A, Jones TV, Curtis JR.
    Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.
    Curtis JR, Schulze-Koops H, Takiya L, Mebus CA, Terry KK, Biswas P, Jones TV.
    Clin Exp Rheumatol; 2017 Nov; 35(3):390-400. PubMed ID: 28079500
    [Abstract] [Full Text] [Related]

  • 31. [Tofacitinib].
    Döker S, Dewenter M, El-Armouche A.
    Dtsch Med Wochenschr; 2014 May; 139(19):1003-8. PubMed ID: 24782154
    [Abstract] [Full Text] [Related]

  • 32. Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art.
    Caso F, Navarini L, Ruscitti P, Chimenti MS, Girolimetto N, Del Puente A, Giacomelli R, Scarpa R, Costa L.
    Expert Opin Pharmacother; 2020 May; 21(7):785-796. PubMed ID: 32057269
    [Abstract] [Full Text] [Related]

  • 33. Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis.
    Kaur K, Kalra S, Kaushal S.
    Clin Ther; 2014 Jul 01; 36(7):1074-86. PubMed ID: 25047498
    [Abstract] [Full Text] [Related]

  • 34. Tofacitinib for psoriatic arthritis (PsA) is now approved by the European Commission.
    Rheumatology (Oxford); 2018 Sep 01; 57(9):e55. PubMed ID: 30137541
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V, Kremer JM, Gruben D, Krishnaswami S, Zwillich SH, Wallenstein GV.
    Arthritis Care Res (Hoboken); 2017 Apr 01; 69(4):592-598. PubMed ID: 27565000
    [Abstract] [Full Text] [Related]

  • 37. [A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].
    Varisco PA, So A.
    Rev Med Suisse; 2014 Jan 22; 10(414):187-91. PubMed ID: 24624736
    [Abstract] [Full Text] [Related]

  • 38. Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab.
    van der Heijde D, Gladman DD, FitzGerald O, Kavanaugh A, Graham D, Wang C, Fallon L.
    J Rheumatol; 2019 Sep 22; 46(9):1089-1096. PubMed ID: 30824647
    [Abstract] [Full Text] [Related]

  • 39. Tofacitinib in the treatment of active rheumatoid arthritis in adults.
    Fleischmann R.
    Immunotherapy; 2018 Jan 22; 10(1):39-56. PubMed ID: 29043892
    [Abstract] [Full Text] [Related]

  • 40. [JAK inhibitor].
    Yamaoka K, Tanaka Y.
    Nihon Rinsho; 2013 Jul 22; 71(7):1243-7. PubMed ID: 23961674
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.